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Transforming growth factor- increases vascular
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mitogen-activated protein kinases pathways
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Dai Yamanouchi, MD, PhD, Drew Roenneburg, MS, Bo Liu, PhD, and K. Craig Kent, MD, Madison, Wisc
Introduction: We have previously demonstrated that transforming growth factor- (TGF-) in the presence of elevated levels of
Smad3, its primary signaling protein, stimulates rat vascular smoothmuscle cell (VSMC) proliferation and intimal hyperplasia. The
mechanism is partly through the nuclear exportationof phosphorylated cyclin-dependent kinase inhibitor p27.The objective of this
study is to clarify thedownstreampathways throughwhichSmad3produces its proliferative effect. Specifically,weevaluated the role
of extracellular signal-regulated kinase (ERK) mitogen-activated protein kinase (MAPK) in TGF-–induced VSMC proliferation.
Methods:Cultured rat aortic VSMCswere incubated with TGF- at varying concentrations and times, and phosphorylated
ERK was measured by Western blotting. Smad3 was enhanced in VSMCs using an adenovirus expressing Smad3 or
inhibited with small interfering RNA (siRNA). For in vivo experiments, male Sprague-Dawley rats underwent carotid
balloon injury, followed by intraluminal infection with an adenovirus expressing Smad3. Arteries were harvested at 3 days
and subjected to immunohistochemistry for Smad3, phospho-ERK MAPK, and proliferating cell nuclear antigen.
Results: In cultured VSMCs, TGF- induced activation and phosphorylation of ERKMAPK in a time-dependent and concentra-
tion-dependent manner. Overexpression of the signaling protein Smad3 enhanced TGF--induced activation of ERK MAPK,
whereas inhibition of Smad3 with a siRNA blocked ERKMAPK phosphorylation in response to TGF-. These data suggest that
Smad3 acts as a signaling intermediate between TGF- and ERK MAPK. Inhibition of ERK MAPK activation with PD98059
completely blocked the ability of TGF-/Smad3 to stimulate VSMCproliferation, demonstrating the importance of ERKMAPK
in thispathway. Immunoprecipitationofphospho-ERKMAPKandblottingwithSmad3revealedaphysical association, suggesting
that activation of ERK MAPK by Smad3 requires a direct interaction. In an in vivo rat carotid injury model, overexpression of
Smad3 resulted in an increase in phosphorylatedERKMAPKaswell as increasedVSMCproliferation asmeasured by proliferating
cell nuclear antigen.
Conclusions:Our findings demonstrate a mechanism through which TGF- stimulates VSMC proliferation. Although TGF- has
been traditionally identified as an inhibitor of proliferation, our data suggest that TGF- enhances VSMC proliferation through a
Smad3/ERKMAPK signaling pathway. These findings at least partly explain the mechanism by which TGF- enhances intimal
hyperplasia.Knowledge of this pathway provides potential novel targets thatmaybe used to prevent restenosis. (JVasc Surg2012;
56:446-54.)
Clinical Relevance: Restenosis continues to be the most significant limitation to the long-term success of surgical
therapies for atherosclerotic-associated diseases. Although transforming growth factor- (TGF-) has been implicated in
the pathogenesis of restenosis, anti-TGF therapies could lead to untoward cell growth because it is a known growth
inhibitor in a number of cell types. This led to the investigation of downstream mediators of TGF-, Smad3, and
extracellular signal-regulated kinase (ERK) mitogen-activated protein kinases (MAPK), as more selective targets to
repress smooth muscle cell proliferation. This study demonstrates that TGF-, through its primary signaling pathway
Smad3, directly activates the ERK MAPK pathway to increase smooth muscle cell proliferation.
Additional material for this article may be found online at www.jvascsurg.org.
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Prevention, atherosclerotic-associated diseases are the lead-
ing cause of death in the United States. However, interven-
tional treatments of atherosclerosis are often complicated
by restenosis or the development of intimal hyperplasia.
Rates of restenosis range from 20% to 80% after coronary or
peripheral angioplasty.1 Restenosis is the sequela of a com-
plex process dominated by the development of plaque in
the subintimal space. Intimal plaque is highly cellular and is
in part the consequence of migration and proliferation of
vascular smooth muscle cells (VSMCs) from the arterial
media, the adventitia, as well as potentially from the bone
marrow.2-4
The role of TGF- in the pathogenesis of restenosis has
been well established.5-8 The prevailing theory has been
that TGF-, which is known for its fibrotic effects, en-
hances intimal hyperplasia through the production of ex-
tracellular matrix proteins, including the various colla-
gens.6,8 Alternatively, our own laboratory has recently
demonstrated that TGF-, in the presence of its primary
signaling protein, Smad3, enhances VSMC proliferation,
and thus in this manner may contribute to the cellularity of
intimal plaque.8 This was a surprising finding, in that we
and others have shown in vitro that TGF- inhibits prolif-
eration of VSMCs and other cell types.9 From our studies,
it appears that persistently high levels of Smad3, which are
coincidentally present at the time of arterial injury, are
required for TGF- to produce its proliferative effect.8
TGF- signals primarily through the Smad pathway,
although a number of non-Smad signaling pathways have
also been described.10,11 TGF- transduces its signal by
binding with type I and type II receptors, leading to
Smad2/3 phosphorylation. The phosphorylated Smad2/3
proteins interact with Smad4, and the entire complex then
translocates and accumulates in the nucleus where it regu-
lates transcription of various target genes.12,13 In addition
to the Smad pathway, TGF- signals through various
Smad-independent signaling pathways such as protein ki-
nases C and A and phosphatidylinositol 3-kinases/Akt.14
We have previously demonstrated that the growth inhibi-
tory effects of TGF- are mediated through a non-Smad
pathway involving the regulation of cyclin A.
The mitogen-activated protein kinases (MAPKs) are a
family of intracellular signaling proteins that regulate a
variety of cellular activities. Extracellular signal-related ki-
nases 1 and 2 (ERK 1/2) are a subfamily of MAPKs that
regulate cellular processes such as transcription and prolif-
eration.15 After binding and activation of a variety of
growth factors, including platelet-derived growth factor, a
cascade of events leads to dual phosphorylation of the two
isoforms of ERK MAPK. Once phosphorylated, ERK
MAPK becomes an active kinase that translocates to the
nucleus, where it has been shown to regulate transcription,
specifically of genes such as cyclin D1, leading to cell-cycle
progression through cytoplasmic sequestration of p27.16
In VSMCs, ERK MAPK has been demonstrated to
increase proliferation and has been implicated in the devel-
opment of restenosis.17 Therefore, we chose to explore Bhether TGF-/Smad3 might produce its proliferative
ffect through the induction of the ERK MAPK pathway.
e report that TGF- through Smad3 is a potent activator
f ERK MAPK both in vitro and in vivo. We found that
ctivation of ERK MAPK by TGF- is a process that is
reatly enhanced by overexpression of Smad3 and inhibited
y a small interfering RNA (siRNA) to Smad3. Moreover,
lockade of ERK MAPK decreases TGF-/Smad3–
nduced VSMC proliferation. Finally, we demonstrate
hat overexpression of Smad3 in vivo enhances expres-
ion of activated ERK MAPK, which is associated with
SMC proliferation. These data suggest a novel mecha-
ism by which TGF-, through Smad3 and ERK MAPK,
egulates VSMC proliferation and the formation of inti-
al hyperplasia.
ETHODS
Reagents. The chemical inhibitor for ERK 1/2
APK (PD98059) was obtained from Calbiochem (San
iego, Calif). Recombinant TGF-1 was purchased from
&D Systems (Minneapolis, Minn). Dulbecco modified
agle medium (DMEM) and cell culture reagents were
rom Invitrogen (Carlsbad, Calif). Other reagents, if not
pecified, were purchased from Sigma (St. Louis, Mo).
Construction of adenoviral vectors and infection.
denoviral vectors expressing Smad3 (AdSmad3) and
reen fluorescent protein (AdGFP, control) were con-
tructed as previously described.18
SMC culture. Rat aortic VSMCs were isolated from
he thoracoabdominal aorta of male Sprague-Dawley rats
ased on a protocol described by Clowes et al18 and main-
ained in DMEM containing 10% fetal bovine serum (FBS)
t 37°C with 5% CO2.
19 Rat VSMCs were infected with
denovirus (3  104 particles/cell) in DMEM containing
% FBS for 4 hours at 37°C, followed by starvation in
MEM containing 0.5% FBS for 24 hours. Efficiency of
iral infection was evaluated using GFP on AdGFP and
dSmad3. In previous experiments, 80% of cells were
nfected and became GFP-positive (data not shown). The
ells were then treated with recombinant TGF-1 (5 ng/
L) or solvent (4 mmol/L HCl with 2% bovine serum
lbumin) for 1 hour.
Knockdown of Smad3 using siRNA. Rat VSMCs
ere plated at 50% to 60% confluence in DMEM contain-
ng 10% FBS in 6-well plates and incubated for 24 hours.
ells were transfected in Opti-MEM I medium with 100
mol of siRNA for Smad3 or control siRNA using
NAiMax transfection reagent as described by the manu-
acturer’s protocol (Invitrogen, Carlsbad, Calif). After 6
ours, the Opti-MEM I medium was replaced with
MEM containing 10% FBS for 12 hours.
Western blotting analysis. Cells were lysed in radioim-
unoprecipitation assay buffer (50 mmol/L Tris, 150 mmol/L
aCl, 1% Nonidet P-40, 0.1% sodium dodecyl sulfate, and 10
g/mL aprotinin). Protein expression was confirmed by immu-
oblotting with the following antibodies: rabbit antiphosphory-
ated ERK1/2 (p-ERK) or total ERK (t-ERK; Cell Signaling,
oston, Mass), rabbit anti-Smad3 (Invitrogen), and mouse anti-
s
e
t
c
R
O
e
M
t
b
t
t
E
A
l
c
m
a
n
e
a
a
t
o

a
s
a
S
w
m
O
p
s
E
V
w
(
f
l
H
T
o
s
E
F
w
f
b
r
M
JOURNAL OF VASCULAR SURGERY
August 2012448 Suwanabol et al-actin (Sigma). After incubation with the appropriate primary
and horseradish peroxidase-conjugated secondary antibodies,
the membranes were developed with enhanced chemilumines-
cence reagent.
Immunoprecipitation. Immunoprecipitation was car-
ried out as previously described.20 Briefly, cells were lysed in
Nonidet P-40 buffer and incubated with 5 g of anti-
Smad3 or isotype-matched immunoglobulin G (IgG) as
control and incubated at 4°C with constant rotation over-
night. Protein A-sepharose beads (Santa Cruz Biotechnol-
ogy, Santa Cruz, Calif) were added and incubated for an
additional 4 hours at 4°C. Precipitated proteins were then
separated by sodium dodecyl sulfate polyacrylamide gel
electrophoresis, then transferred to nitrocellulose mem-
branes and immunoblotted with rabbit antiphosphorylated
Smad3 or p-ERK.
Cell viability assay. Cell viability was determined
by modified MTT (3-[4,5-dimethyl-thiazol-2-yl]-2,5-
diphenyltetrazolium bromide) assay.21 Cells were plated at
50% to 60% confluence on 24-well plates and treated as
described above. Cells were then washed with phosphate-
buffered saline, and 25 L MTT solution (0.5 mg/mL) in
phenol red-free culture medium (0.5% fetal calf serum) was
added to each well and incubated for 2 hours at 37 °C. The
MTT was aspirated, and 500 L acidic isopropanol (0.04
mol/L HCl) was added for 10 minutes to solubilize the
intracellular formazan product. Absorbance was measured
at 570 nm using absorbance at 690 nm to correct for
background. MTT was measured as a fold-change from
control cells.
Rat balloon injury model and in vivo gene delivery.
Male Sprague-Dawley rats (300-350 g) underwent balloon
injury of the left common carotid artery as described else-
where in accordance with institutional guidelines and ap-
proval.20 Briefly, after induction of anesthesia with isoflu-
rane, a 2F balloon catheter was inserted through the left
external carotid artery into the common carotid artery and
insufflated with 2 atm of pressure three times. After injury,
the animals received intraluminal administration of adeno-
virus vectors (2.5 109 plaque-forming units in 200 L of
phosphate-buffered saline over 20 minutes). The external
carotid artery was then ligated, and flow was re-established
through the common carotid and internal carotid arteries.
Rats were euthanized 3 days after injury and fixed in 4%
paraformaldehyde overnight for embedding in paraffin.
Immunohistochemistry. Paraffin-embedded arteries
were cut into 6-m sections for analysis. Immunostaining
for Smad3, p-ERK, and proliferating cell nuclear antigen
(PCNA) was performed as described previously.18 Anti-
body controls included detection of species-matched IgG.
Five immunostained sections from each animal were
then chosen. Each section was imaged from six different
fields at original magnification 200. Two independent
investigators manually counted the number of positive
cells. These numbers were compounded to generate the
mean and standard deviation for that animal. The means
were averaged, and the standard error of the mean was
calculated for each group. aStatistical analysis. Data are expressed as mean 
tandard error. An unpaired Student t-test was used to
valuate the statistical differences between control and
reated groups. Values of P  .05 were considered signifi-
ant. All experiments were repeated at least three times.
ESULTS
TGF- induces ERK MAPK activation in VSMCs.
ur previous studies have demonstrated that TGF-/Smad3
nhances VSMC proliferation both in vitro and in vivo.8 ERK
APK is known to stimulate proliferation in multiple cell
ypes, including VSMCs.15 Thus, we evaluated whether incu-
ation of VSMCs with TGF- would enhance phosphoryla-
ion of ERK MAPK (p-ERK) as measured by Western blot-
ing. We first evaluated whether TGF-–induced activation of
RK MAPK is in a concentration-dependent manner (Fig 1,
). Stimulation for 1 hour with TGF- at concentrations as
ow as 1 ng/mL enhanced activation of ERK MAPK with
ontinued activation at concentrations as high as 10 ng/
L. We then evaluated the time course of ERK MAPK
ctivation by TGF- (Fig 1, B). At a concentration of 5
g/mL, TGF- enhanced ERK MAPK phosphorylation as
arly as 15 minutes, peaking at 60 minutes and decreasing
t 2 hours. Similarly, activation of SMCs with TGF- does
lso lead to phosphorylation of Smad3, albeit much quicker
han ERK MAPK (Supplementary Fig 1, A and B, online
nly). Thus, our findings demonstrate that despite TGF-
’s known antiproliferative effect, this cytokine has a strong
nd reproducible ability to activate the proproliferative
ignaling protein ERK MAPK.
TGF-–induced ERK MAPK activation is medi-
ted through the intracellular signaling protein,
mad3. In the next series of experiments, we evaluated
hether the observed activation of ERK MAPK by TGF-
ight be mediated through the signaling protein Smad3.
ur previous studies demonstrating that TGF- induces
roliferation in the presence of elevated levels of Smad3
uggest a possible role for Smad3 in TGF-’s activation of
RK MAPK. We began by overexpressing Smad3 in
SMCs (Supplementary Fig 2, A, online only). VSMCs
ere infected with adenovirus expressing Smad3 or GFP
control), followed by stimulation with TGF- (5 ng/mL)
or 1 hour (Fig 2, A). Overexpression of Smad3 alone had
ittle effect on ERK MAPK phosphorylation (Fig 2, A).
owever, stimulation of cells overexpressing Smad3 with
GF- dramatically enhanced TGF-–induced activation
f ERK MAPK.
To further demonstrate the importance of Smad3 as a
ignaling intermediate in TGF-–induced activation of
RK MAPK, we used an siRNA to Smad3 (Supplementary
ig 2, B, online only). VSMCs were pretreated for 24 hours
ith scrambled or Smad3 siRNA, followed by incubation
or 1 hour with TGF- (5 ng/mL). We used Western
lotting to measure p-ERK (Fig 2, B). Inhibition of Smad3
esulted in a marked decrease in the activation of ERK
APK. The foregoing data suggest that TGF-–induced
ctivation of ERK MAPK is dependent on Smad3.
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Volume 56, Number 2 Suwanabol et al 449Activation of ERK MAPK by Smad3 requires a
direct protein–protein interaction. Smad3 produces its
effect through gene transcription. Receptor activation by TGF-
leads to Smad2/3 phosphorylation, followed by translocation of
these proteins along with Smad4 to the nucleus where this
complex is directly involved in the transcriptional regulation of
various target genes. Our finding that TGF- through Smad3
produces ERK MAPK activation 15 minutes would suggest
Fig 1. Transforming growth factor- (TGF-) induces e
protein kinase phosphorylation in vascular smooth musc
hour at the indicated concentrations. B, VSMCs were t
Protein lysates were analyzed by Western blotting us
(t-ERK), or -actin. Data are shown with the standard e
experiments. *P  .05.
Fig 2. Smad3 is a signaling intermediate in transform
extracellular signal-regulated kinase (ERK) mitogen-a
(VSMCs) were infected with control virus adenovirus
(AdSmad3), followed by stimulation with TGF- (5 ng/
of control small interfering RNA (siRNA; scramble) or w
with TGF- for 1 hour. Protein lysates were analyzed
(p-ERK), total ERK (t-ERK), or -actin. Data are shown
three independent experiments. *P  .05.that gene transcription is not involved. pWe thus postulated the requirement of a more direct
rotein–protein interaction between Smad3 and ERK
APK. To test the presence of a physical association be-
ween these two proteins, we used the technique of immu-
oprecipitation. We overexpressed Smad3 in VSMCs and
timulated for 1 hour with TGF- (5 ng/mL). Cell lysate
as immunoprecipitated with an antibody to Smad3 or
sotype-matched IgG control and blotted for p-ERK and
ellular signal-regulated kinase (ERK) mitogen-activated
ls (VSMCs). A, VSMCs were treated with TGF- for 1
with TGF- (5 ng/mL) at the indicated time points.
ntibodies against phospho-ERK (p-ERK), total ERK
range bars) and are representative of three independent
rowth factor- (TGF-)–induced phosphorylation of
ed protein kinase. A, Vascular smooth muscle cells
essing green fluorescent protein (AdGFP) or Smad3
for 1 hour. B, VSMCs were transfected with 100 pmol
00 pmol of Smad3 siRNA for 24 hours then stimulated
estern blotting using antibodies against phospho-ERK
the standard error (range bars) and are representative ofxtrac
le cel
reated
ing a
rror (ing g
ctivat
expr
mL)
ith 1
by W
with-Smad3. As shown in Fig 3, Smad3 and p-ERK MAPK are
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August 2012450 Suwanabol et alassociated with endogenous Smad3, and overexpression of
Smad3, followed by stimulation with TGF-, further en-
hances the association. These data demonstrate that Smad3
and p-ERK MAPK coassociate, suggesting that Smad3
activates ERK MAPK through a direct interaction.
Inhibition of ERK MAPK decreases TGF-/
Smad3-induced cell proliferation. We previously dem-
onstrated that TGF-/Smad3 increases VSMC prolifer-
ation and showed in the forgoing experiments that TGF-
/Smad3 activates ERK MAPK. The final link was to
demonstrate that the effect of TGF-/Smad3 on VSMC
proliferation is mediated by ERK MAPK. To accomplish
this, we used a selective inhibitor of ERK MAPK,
PD98059. VSMCs were infected with AdGFP or AdS-
mad3 and pretreated or not with PD98059 (10 m/mL)
for 30 minutes, followed by stimulation with TGF- (5
ng/mL) for 96 hours. Proliferation was measured using
an MTT assay. We confirmed that TGF-/Smad3 in-
creases VSMC proliferation compared with control (Fig
4) and then demonstrated that inhibition of ERK MAPK
completely eliminates the enhancement in VSMC prolif-
eration produced by TGF-/Smad3. These and the pre-
ceding experiments provide conclusive proof that the
stimulatory effect of TGF- on VSMC proliferation is
mediated through a pathway that involves both Smad3 as
well as ERK MAPK.
Smad3 enhances ERK MAPK activation in an in
vivo model of arterial injury. Our in vitro findings sug-
gest that TGF- along with Smad3 enhances VSMC pro-
liferation through activation of ERK MAPK. To verify
these findings in vivo, we used a rat carotid injury model of
intimal hyperplasia. Rat carotid arteries were balloon-
injured, as previously described, and infused immediately
after injury with AdSmad3 or AdGFP for 30 minutes.
Animals were euthanized at 3 days, and immunohisto-
Fig 3. Western blotting (WB) and immunoprecipitation (IP)
show a direct protein–protein interaction between Smad3 and
phosphorylated extracellular signal-regulated kinase (p-ERK)
mitogen-activated protein kinase. Vascular smooth muscle cells
(VSMCs) were infected with control adenovirus expressing green
fluorescent protein (AdGFP) or Smad3 (AdSmad3), followed by
stimulation with transforming growth factor- (TGF-; 5 ng/mL)
for 1 hour. Cell lysates were immunoprecipitated with anti-Smad3
antibody (Ab) or immunoglobulin G and immunoblotted for
p-ERK or phosphorylated Smad3 (p-Smad3). Data shown are
representative of three independent experiments.chemistry was performed using IgG as well as antibodies to mmad3, p-ERK MAPK, and PCNA (Fig 5). As anticipated,
verexpression of Smad3 resulted in a dramatic increase in
he number of Smad3-positive cells. Furthermore, in the
nimals overexpressing Smad3, there was an almost 50%
ncrease in the number of cells expressing p-ERK MAPK
AdGFP 32.4  2.65 vs AdSmad3 63.5  6.5). Finally,
verexpression of Smad3 with the resultant enhancement
f p-ERK MAPK was associated with a substantial increase
n VSMC proliferation as demonstrated by PCNA (AdGFP
3.1  2.4 vs AdSmad3 68.3  4.65). Our findings
uggest that in vivo (although only through association),
GF-/Smad3 enhances VSMC proliferation through a
echanism that involves ERK MAPK.
ISCUSSION
TGF- plays an indisputable role in the development of
ntimal hyperplasia. Levels of TGF- increase dramatically
fter arterial injury, and blocking TGF- via a number of
echanisms very significantly inhibits the arterial hyper-
lastic response. Intimal hyperplasia is associated with en-
anced VSMC proliferation and migration, posing a co-
undrum since TGF- has been shown in vitro to be an
nhibitor of both of these processes.9 Potentially resolving
his discrepancy, our recent studies suggest that under
ircumstances present at the time of arterial injury (specif-
cally in the presence of elevated levels of Smad3), TGF-
ignificantly enhances proliferation of VSMCs. We, in ad-
ition to a number of other investigators, have demon-
trated that Smad3 is upregulated after arterial injury in
nimals.8,22-24 Moreover, we have demonstrated that most
mad3-expressing cells also express the proliferating
ig 4. Extracellular signal-regulated kinase inhibition decreases
ransforming growth factor- (TGF-)/Smad3-induced vascular
mooth muscle cell (VSMC) proliferation. VSMCs were infected
ith adenovirus expressing green fluorescent protein (AdGFP;
ontrol) or Smad3 (AdSmad3). These cells were then pretreated
or 30 minutes with the extracellular signal-regulated kinase
ERK) mitogen-activated protein kinase inhibitor PD98059 (10
m/mL) or control, followed by stimulation with TGF- (5 ng/mL)
r solvent for 96 hours. Proliferation was evaluated by 3-[4,5-dimeth-
l-thiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay (n
). *P .05 comparison of Smad3 or Smad3TGF- vs GFP alone;
*P .05 comparison of Smad3 or Smad3TGF-with or without
D98059. Data are shown with the standard error (range bars).arker PCNA.8 These findings have been made by our
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Volume 56, Number 2 Suwanabol et al 451laboratory in human restenotic lesions as well.25 Thus, the
findings of our experiments where we have overexpressed
Smad3 both in vitro and in vivo likely have physiologic
relevance in that a similar state is found after arterial injury.
We postulate that enhancement of VSMC proliferation by
TGF-may be the primary mechanism through which this
cytokine mediates intimal hyperplasia.
The purpose of the current study was to better under-
Fig 5. Overexpression of Smad3 in vivo increases pho
mitogen-activated protein kinase and cell proliferation
injured, followed by infusion with adenovirus expressing
units) or adenovirus expressing green fluorescent protei
euthanized at day 3, and arteries were subjected to para
performed with immunoglobulin G (IgG), Smad3, pERK
percentage of immunopositive cells was calculated. Left,
Right, Bar graphs show quantitative results for p-ERK
PCNA (AdGFP 43.1 2.4 vs AdSmad3 68.3 4.65).
(**P  .01).stand the signaling mechanism through which TGF- pro- wuces its proliferative effect, and we have demonstrated that
GF- activates ERK MAPK through a pathway involving
mad3. We have also demonstrated a protein–protein in-
eraction between Smad3 and activated ERK MAPK and
hown that blocking ERK MAPK decreases TGF-/
mad3-induced VSMC proliferation. Our in vivo data
emonstrate that in injured arteries overexpressing Smad3,
here is increased expression of activated ERK MAPK as
ylation of extracellular signal-regulated kinase (pERK)
injured artery wall. Rat carotid arteries were balloon-
3 for 20 minutes (AdSmad3, 2.5 109 plaque-forming
GFP, 2.5  109 plaque-forming units). Animals were
mbedding and sectioning. Immunohistochemistry was
oliferating cell nuclear antigen (PCNA) antibodies. The
unohistochemistry for IgG, Smad3, p-ERK, and PCNA.
K (AdGFP 32.4 2.65 vs AdSmad3 63.5  6.5) and
shown are representative of three animals per groupsphor
in the
Smad
n (Ad
ffin e
or pr
Imm
MAP
Dataell as enhanced VSMC proliferation. Together, these data
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MAPK may have a significant role in the development of
intimal hyperplasia in response to TGF-.
In our initial exploration of the signaling pathways
through which TGF- mediates SMC proliferation, we
studied the cyclin-dependent kinase inhibitor p27.8 Nu-
clear p27 acts as a potent cell cycle inhibitor, whereas
phosphorylation of p27 results in translocation of this
protein out of the nucleus, allowing the cell cycle to prog-
ress. We found that TGF- and Smad3 were able to signif-
icantly enhance VSMC proliferation by promoting nuclear
exportation of p27. Phosphorylation of p27 is a very down-
stream event in the cellular pathways that lead to prolifer-
ation. Thus, in evaluating ERK MAPK, we searched for a
connection between Smad3 and p27. MAPK has been
found to downregulate p27 expression, increase the degra-
dation of p27, and enhance cytoplasmic sequestration of
p27. The effect of all of these events is to eliminate the
nuclear inhibition by p27 of cell cycle proteins, resulting in
enhancement of proliferation. Thus, the identification of a
role for ERK MAPK in TGF-–induced VSMC prolifera-
tion reveals ERK MAPK to be the likely connection be-
tween TGF-/Smad3 and p27.
The role of ERK MAPK in cellular proliferation, spe-
cifically VSMC proliferation, is well established. ERK
MAPK activation occurs in response to a variety of cyto-
kines and growth factors, leading to both the passage of cell
cycle checkpoints as well as the activation of transcription
factors related to cell proliferation.26,27 We and others have
shown that in cultured VSMCs, ERK MAPK plays a critical
role in both proliferation and migration.9,28 In vivo studies
have demonstrated the significance of ERK MAPK in the
development of intimal hyperplasia. Hu et al29 showed that
in a rat carotid balloon injury model, there was increased
expression of activated ERK MAPK peaking at 5 minutes
with elevated levels sustained for up to 7 days after injury.
Furthermore, extraluminal application of the chemical in-
hibitor to ERK MAPK PD98059, which was used in our
experiments, decreased the development of intimal hyper-
plasia.30 Whether ERK MAPK is the sole pathway through
which TGF- enhances VSMC proliferation is not clear.
Recent studies from our laboratory suggest that other
members of the MAPK family, specifically p38, may act as
intermediates between TGF-/Smad3 and VSMC prolif-
eration. These studies reveal a completely distinct pathway
from ERK MAPK for proliferation involving p38 as well as
Akt (unpublished data). Thus, it may well be that TGF-
produces its proliferative effect through a number of paral-
lel pathways.
Our data reveal a pathway involving ERK MAPK acti-
vation that is downstream from Smad3. There are examples
in other cell types where TGF- has been found to modu-
late MAPK through a Smad-dependent pathway. Zhang et
al31 found that TGF- activates ERK MAPK in pancreatic
acinar cells through a pathway that involves Smad4. More-
over, Smad4 has been found to directly affect MAPK in
other cell types.31,32 MTGF- is also known to signal through independent
athways. Smad-independent pathways used by TGF-
nclude c-Jun N-terminal kinase, protein kinases A and C,
nd phosphatidylinositol 3-kinases/Akt. These pathways
re thought to modulate the effects of TGF- that require
apid activation. This is contrary to the Smad pathways that
re typically involved in transcriptional regulation of
enes.33 Accordingly, a relationship between TGF- and
RK MAPK that is independent of Smads has been previ-
usly described in a number of cell types. In VSMCs,
GF- through a Smad-independent pathway can enhance
roduction of collagen as well as biglycans.34,35 TGF-,
lso in a Smad-independent manner, can activate ERK
APK in chondrocytes, epithelial cells, and hepatic stellate
ells.36,37 The exact molecular mechanism by which TGF-
ctivates ERK MAPK in these cells has not been clearly de-
ned, but the Ras/Raf signaling pathway may act as an inter-
ediate. Despite the existence of Smad-independent signal-
ng pathways, however, our data fairly conclusively show
hat when VSMC proliferation is the end point, TGF-
ctivated ERK MAPK through a Smad-dependent vs a
mad-independent pathway.
In another variation in the relationship between these
wo signaling proteins, ERK MAPK has been found to act
pstream rather than downstream of the Smad pro-
eins.38,39 Studies have shown that ERK MAPK can en-
ance Smad activation and translocation into the nu-
leus.34,40 In VSMCs, for example, ERK MAPK has been
hown to phosphorylate Smad2 at its linker region.34 A
imilar observation has been made in rat mesangial cells,
eading to an increase in collagen IV expression.41 There
re examples of MAPK being upstream from other mem-
ers of the TGF- superfamily, including bone morphoge-
etic proteins in human umbilical vein endothelial
ells.42,43 These data, along with our new observation that
mad3 can activate MAPK, suggests the potential for a
ositive feedback loop between these two proteins. This
ositive feedback loop, if it exists, might have the potential
o greatly enhance the effect of TGF- on VSMC prolifer-
tion.
Smads have been traditionally thought to influence cell
unction through gene regulation. In fact, Aoki et al44
emonstrated in pancreatic stellate cells that TGF-
hrough Smad3 induces secretion of interleukin-1, which
n turn signals through ERK MAPK to further enhance cell
ecretion. However, because stimulation of VSMCs with
GF- results in phosphorylation of ERK MAPK as early as
5 minutes and because Smad3 is the intermediate, these
ndings raise the possibility that Smad3 may immediately
nd directly interact with ERK MAPK, leading to its acti-
ation. Further supporting this hypothesis is that our im-
unoprecipitation studies reveal a direct protein–protein
nteraction between Smad3 and ERK MAPK.
ONCLUSIONS
We demonstrate a mechanism in VSMCs by which
GF- activates Smad3, which in turn activates ERK
APK leading to VSMC proliferation. Moreover, our in
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Volume 56, Number 2 Suwanabol et al 453vitro findings are supported by in vivo studies using a rat
carotid injury model. Although the mechanism by which
TGF- enhances intimal hyperplasia has not been fully
elucidated, TGF-–induced VSMC proliferation through
this signaling pathway is a likely contributor. Manipulation
of TGF- or the various components of its signaling path-
way may prove useful in creating targets that allow inhibi-
tion of the devastating and ubiquitous process that leads to
restenosis.
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